Key result
Diallyl trisulfide (DATS) administration reduced infarct size compared with control and improved myocardial contractile function 72 hours after reperfusion.
Why the study?
Does diallyl trisulfide (DATS) reduce infarct size and improve cardiac function in a mouse model of myocardial ischemia-reperfusion injury?
Does diallyl trisulfide (DATS) reduce infarct size and improve cardiac function in a mouse model of myocardial ischemia-reperfusion injury?
Answers are grounded in this paper and cite their sources.
DATS acts as a hydrogen sulfide donor that protects against myocardial ischemia-reperfusion injury by reducing infarct size and preserving cardiac function in a murine model.
Diallyl trisulfide (DATS), a polysulfide constituent found in garlic oil, is capable of the release of hydrogen sulfide (H(2)S). H(2)S is a known cardioprotective agent that protects the heart via antioxidant, antiapoptotic, anti-inflammatory, and mitochondrial actions. Here, we investigated DATS as a stable donor of H(2)S during myocardial ischemia-reperfusion (MI/R) injury in vivo. We investigated endogenous H(2)S levels, infarct size, postischemic left ventricular function, mitochondrial respiration and coupling, endothelial nitric oxide (NO) synthase (eNOS) activation, and nuclear E2-related factor (Nrf2) translocation after DATS treatment. Mice were anesthetized and subjected to a surgical model of MI/R injury with and without DATS treatment (200 μg/kg). Both circulating and myocardial H(2)S levels were determined using chemiluminescent gas chromatography. Infarct size was measured after 45 min of ischemia and 24 h of reperfusion. Troponin I release was measured at 2, 4, and 24 h after reperfusion. Cardiac function was measured at baseline and 72 h after reperfusion by echocardiography. Cardiac mitochondria were isolated after MI/R, and mitochondrial respiration was investigated. NO metabolites, eNOS phosphorylation, and Nrf2 translocation were determined 30 min and 2 h after DATS administration. Myocardial H(2)S levels markedly decreased after I/R injury but were rescued by DATS treatment (P < 0.05). DATS administration significantly reduced infarct size per area at risk and per left ventricular area compared with control (P < 0.001) as well as circulating troponin I levels at 4 and 24 h (P < 0.05). Myocardial contractile function was significantly better in DATS-treated hearts compared with vehicle treatment (P < 0.05) 72 h after reperfusion. DATS reduced mitochondrial respiration in a concentration-dependent manner and significantly improved mitochondrial coupling after reperfusion (P < 0.01). DATS activated eNOS (P < 0.05) and increased NO metabolites (P < 0.05). DATS did not appear to significantly induce the Nrf2 pathway. Taken together, these data suggest that DATS is a donor of H(2)S that can be used as a cardioprotective agent to treat MI/R injury.
No takes yet. Share an insight, caveat, or question.
Predmore et al. (2012) studied Myocardial ischemia-reperfusion (MI/R) injury. Diallyl trisulfide (DATS) vs. control / vehicle was evaluated on Infarct size per area at risk and per left ventricular area (p=<0.001). Diallyl trisulfide (DATS) administration reduced infarct size compared with control and improved myocardial contractile function 72 hours after reperfusion.
Synapse has enriched 10 related papers. Consider them for comparative context: